Compare HURN & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HURN | TLX |
|---|---|---|
| Founded | 2002 | 2015 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.2B |
| IPO Year | 2004 | N/A |
| Metric | HURN | TLX |
|---|---|---|
| Price | $124.94 | $8.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $215.50 | $21.13 |
| AVG Volume (30 Days) | 292.4K | ★ 300.1K |
| Earning Date | 04-28-2026 | 04-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 5.84 | N/A |
| Revenue | ★ $1,699,143,000.00 | N/A |
| Revenue This Year | $11.74 | N/A |
| Revenue Next Year | $10.55 | N/A |
| P/E Ratio | ★ $22.27 | $150.33 |
| Revenue Growth | ★ 11.65 | N/A |
| 52 Week Low | $116.12 | $6.28 |
| 52 Week High | $186.78 | $19.93 |
| Indicator | HURN | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 34.33 | 64.04 |
| Support Level | $118.18 | $7.72 |
| Resistance Level | $138.06 | $9.92 |
| Average True Range (ATR) | 4.92 | 0.26 |
| MACD | 0.09 | 0.15 |
| Stochastic Oscillator | 1.08 | 81.14 |
Huron Consulting Group Inc is a professional services firm. The company provides expertise in technology, operations, advisory services, & analytics through three operating segments namely Healthcare, Education, and Commercial. Healthcare segment helps the firms to transform and innovate the delivery model to focus on patient wellness by improving quality outcomes, minimizing care variation and fundamentally improving patient and population health, Education segment provides management consulting and technology solutions, and Commercial segment is focused on serving industries and organizations facing disruption and regulatory change. It generates a majority of its revenue from the Healthcare Segment.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.